FULC

NASDAQ open

Fulcrum Therapeutics

3.69 USD
▼-0.03-0.67%
盘后 3.67 0.00%
2026-11-20
市值
$281.85M
市盈率
—
EPS
-1.04
股息率
—
52 周区间
2.83 – 15.74
成交量
1.18M
Beta
2.77
目标价
3.67
52W 低 2.8352W 高 15.74
价格走势

公司简介

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, ...

关联新闻